Publications by authors named "Marlene Mathuber"

Claim this Profile
T
The anticancer thiosemicarbazone triapine exerts immune-enhancing activities via immunogenic cell death induction and FAS upregulation.
Bianca Stiller, Alessia Stefanelli, Hemma Schueffl, Marlene Mathuber, Nadiya Skorokhyd

Exp Hematol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692.
Orsolya Dömötör, Marlene Mathuber, Christian R Kowol

Eur J Pharm Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
Monika Caban, Bettina Koblmueller, Diana Groza, Hemma H Schueffl, Alessio Terenzi, Marlene Mathuber

Cancer Lett· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance.
Vivien Pósa, Alessia Stefanelli, Julia H Bormio Nunes, Sonja Hager, Marlene Mathuber

Cancers (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes.
Marlene Mathuber, Sonja Hager, Bernhard K Keppler, Petra Heffeter, Christian R Kowol

Dalton Trans· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a cobalt(iii)-based ponatinib prodrug system.
Marlene Mathuber, Michael Gutmann, Mery La Franca, Petra Vician, Anna Laemmerer

Inorg Chem Front· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs.
Marlene Mathuber, Hemma Schueffl, Orsolya Dömötör, Claudia Karnthaler, Éva A Enyedy

Inorg Chem· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux.
Julia H Bormio Nunes, Sonja Hager, Marlene Mathuber, Vivien Pósa, Alexander Roller

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, Characterization and in vitro Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib.
Claudia Karnthaler-Benbakka, Bettina Koblmüller, Marlene Mathuber, Katharina Holste, Walter Berger

Chem Biodivers· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis